Cambridge University to trial new preventive Covid-19 treatments

The government-backed ‘Protect-V’ trials will test drugs that may increase the survival chances of clinically vulnerable patients

Niclosamide may prevent the most vulnerable from contracting Covid-19Lucas Maddalena

by Luke Hallam

This article is 5 years old

Tuesday March 23 2021, 3:39pm

A University of Cambridge-led trial is set to test innovative treatments that may prevent the most vulnerable from contracting Covid-19.

The ‘Protect-V’ trial, which has received Urgent Public Health status from the National Institute for Health Research (NIHR), began this month and is expected to last for 12 months.

It will test drugs such as niclosamide – currently used to treat tapeworm infections – for their effectiveness at preventing Covid-19 in care home residents, immunocompromised patients with kidney disease, those on dialysis, and those with a kidney transplant. Niclosamide has been reported as a potential antiviral drug for SARS-CoV-2.

The aim of the trials is to determine whether these patients can be granted protection “over and above” that given by a vaccine.

2,250 people are expected to take part in the trial, out of the estimated 500,000 nationwide who could benefit from preventive drug treatments.

The government has contributed £1.5 million in funding for the trials.

Cambridge economy continues to grow due to science and technology sectors

Dr Rona Smith, Senior Research Associate for Protect-V at Cambridge, said: “Covid-19 has had a huge impact on the lives of these patients. The rapid roll out of vaccination has been very welcome news, but it is unclear if these patients will mount as strong responses to the vaccine as healthy individuals.”

“The government plans for any treatment deemed safe and effective during the trials to be “rapidly made more widely available on the NHS.”

In March 2020, similar trials began in the UK on the steroid dexamethasone, and the resulting treatment has been widely praised for its success in increasing Covid-19 survival, with NHS England estimates suggesting that the steroid has so far saved the lives of 22,000 people in the UK .

Support Varsity

Varsity is the independent newspaper for the University of Cambridge, established in its current form in 1947. In order to maintain our editorial independence, our print newspaper and news website receives no funding from the University of Cambridge or its constituent Colleges.

We are therefore almost entirely reliant on advertising for funding and we expect to have a tough few months and years ahead.

In spite of this situation, we are going to look at inventive ways to look at serving our readership with digital content and of course in print too!

Therefore we are asking our readers, if they wish, to make a donation from as little as £1, to help with our running costs. Many thanks, we hope you can help!